China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting the Turkiye-based firm exclusive distribution and marketing rights to its BAT2206, a biosimilar version of Roche’s Stelara (Ustekinumab).
Partnership Details
Under the agreement, World Medicine will handle the import, regulatory filing, and sales of the drug in Turkiye. Bio-Thera will be responsible for research and development, manufacturing, and commercial supply.
Drug Profile
Stelara, the world’s first all-human “dual-targeted” interleukin 12 (IL-12) and interleukin 23 (IL-23) inhibitor, has secured five indication approvals in the US, covering ulcerative colitis, Crohn’s disease, active psoriatic arthritis, and psoriasis in addition to plaque psoriasis. First approved in China in 2017, Stelara has paved the way for biosimilars like Bio-Thera’s BAT1706, which is awaiting regulatory decisions in multiple regions.-Fineline Info & Tech
Leave a Reply